A step towards treating KRAS-mutant NSCLC

The Lancet Oncology

Volumn 14, Issue 1, 2013, Pages 3-5

  Goldberg, Sarah B ^a,b   Schlessinger, Joseph ^a,b   Boyer, Julie L ^a,b   Herbst, Roy S ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE LKB1; PROTEIN P53; SELUMETINIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; DRUG EFFICACY; FEBRILE NEUTROPENIA; GENE MUTATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BENZIMIDAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TAXOIDS;

EID: 84871716531     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70528-4     Document Type: Letter

References (12)

1. Herbst RS, Heymach JV, Lippman SM Lung cancer. N Engl J Med 2008, 359:1367-1380.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 2011, 13:39-51.
5. Sousa SF, Fenandes PA, Ramos MJ Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem 2008, 15:1478-1492.
6. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997, 272:14459-14464.
7. Jänne PA, Shaw AT, Rodrigues Pereira J, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2012, published online Nov 28. http://dx.doi.org/10.1016/S1470-2045(12)70489-8.
8. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
9. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
10. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
11. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012, 104:228-239.
12. Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483:613-617.